Austria
Brazil
Canada
Czech Republic
France
Germany
Hungary
Mauritius
Netherlands
Netherlands OSS
Poland
Spanish Latin America
Spain
Switzerland
China
Japan
Malaysia
Philippines
Taiwan
Ethicare
Fine Chemicals Corporation
Holdings
Beta Healthcare
Kama
Nigeria
ShelysPhysician News
IMPORTANT NOTIFICATION: Zantac (Ranitidine) Recall
Dear Doctor, Aspen Pharmacare Australia Pty Ltd, in consultation with the Therapeutic Goods Administration (TGA), is conducting a retail level recall of Zantac (ranitidine) tablets, effervescent tablets, syrup and ampoules. The TGA has not requested that a Dear Doctor letter be sent for this retail level product recall. We are informing you as the potentially…
Read MoreANNOUNCEMENT – Aspen Pharmacare – Potential Contamination of Ranitidine with NDMA
On Thursday evening 19th September 2019 the TGA announced the requirement for all sponsors of ranitidine to suspend supply, and initiate a product hold, at their warehouses. Therefore as of Friday 20th September 2019 Aspen has suspended the supply of all Zantac® products to pharmacy wholesalers and to all retailers. Download Letter
Read MoreANNOUNCEMENT – Aspen Pharma – QUARANTINE STATUS LIFTED and PRODUCT DEFECT CORRECTION – ENDONE oxycodone hydrochloride 5mg tablet pack
It has been incorrectly reported in the media that Endone 5mg tablets are the subject of a product recall. Aspen Pharma wishes to advise that there is currently NO RECALL of this medicine. The quarantine placed on the product from the above batch has been lifted, Endone is available for prescribing and dispensing. Download Letter…
Read MoreANNOUNCEMENT – Aspen Pharmacare – Stock status notification for ZYBANSR(Bupropion hydrochloride)150 mg tablets
Aspen Pharmacare Australia wish to notify you that we are experiencing an ongoing supply disruption which has resulted in a long term out of stock status for ZYBANSR(Bupropion hydrochloride)150 mg tablets.
Read MoreANNOUNCEMENT – Aspen Pharmacare – LIVIAL® (tibolone) returning to MSD
Aspen wishes to advise you that responsibility for LIVIAL® (tibolone) will be returning to MSD, who are the Sponsor of this product, effective 1 June 2018.
Read MoreANNOUNCEMENT – Aspen Pharmacare – Notification of some Marcain, Xylocaine and Naropin Product Shortage
Following on from the notification Aspen sent (dated 29th March 2018) regarding Marcain, Xylocaine and Naropin product shortages due to a fire at AstraZeneca’s (AZ) Swedish manufacturing site, Aspen would like to provide you with the following update:
Read MoreANNOUNCEMENT – Aspen Pharmacare – DISCONTINUATION OF DI-GESIC
Aspen Pharmacare wish to advise that Di-Gesic will be discontinued effective 1 April 2018. Regrettably, Aspen has been unable to procure suitable Active Pharmaceutical Ingredient to continue manufacture and supply of Di-Gesic in Australia. The Therapeutic Goods Administration has been notified and the product has been placed on the “Medicine Shortages Information” list. Please see the attached letter for further information.
Read MoreANNOUNCEMENT – Aspen Pharmacare – Notification of some Marcain®, Xylocaine® and Naropin® Product Shortage
Aspen is currently experiencing stock shortages for a range of local anaesthetic products. We are currently working in collaboration with our supplier, AstraZeneca (AZ) to expedite the re-establishment of adequate supply to all markets.
Read MoreANNOUNCEMENT – Aspen Pharmacare – DISCONTINUATION OF DI-GESIC(dextropropoxyphene Hcl 32.5 mg. paracetamol 325 mg)
Aspen Pharmacare advises that Di-Gesic will be discontinued effective 1 April 2018.
Read MoreANNOUNCEMENT – Aspen Pharmacare – ASPEN FENTANYL (fentanyl citrate) injection is back in stock
Aspen is pleased to advise that both presentations of ASPEN Fentanyl injection are back in stock in Australia and are available to order from your wholesaler.
Read More
Australia 
New Zealand 
Austria 
France 
Netherlands-Aspen API 
SPAIN 
SWITZERLAND 
Czech Republic 
POLAND 
Russia 
Slovakia 
Brazil 
Mexico 
MAURITIUS 
Nigeria 
South Africa-HOLDINGS 
MENAT 
USA 
